黄斑变性
哌加他尼
适体
医学
发病机制
药品
血管内皮生长因子
贝伐单抗
临床试验
药理学
癌症研究
血管抑制剂
生物信息学
免疫学
血管内皮生长因子受体
生物
眼科
内科学
遗传学
化疗
作者
Jin‐Chun Lu,Xiaojing Sun
出处
期刊:Chinese Journal of Ocular Fundus Diseases
日期:2017-07-25
卷期号:33 (04): 427-431
标识
DOI:10.3760/cma.j.issn.1005-1015.2017.04.028
摘要
Vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and complements play key roles in the pathogenesis of age-related macular degeneration (AMD). Pegaptanib, the first therapeutic aptamer against VEGF165, has been approved by the Food and Drug Administration (FDA) of US for the treatment of exudative AMD. Another two aptamers E10030 and ARC1905, each target PDGF-B and complement C5 respectively, are undergoing clinical trials. Recent trends to treat AMD are combined therapies targeting multiple key molecules in the pathogenesis of AMD; aptamers against multiple targets may become the preferred drug for AMD.
Key words:
Macular degeneration/therapy; Aptamers, nucleotide/therapeutic use; Review
科研通智能强力驱动
Strongly Powered by AbleSci AI